GSK/Vir’s Covid Antibody Gains EU Clearance, But Demand May Have Peaked

Vaccinations Will Weaken Demand

 
• By Andrew McConaghie

The green light for the COVID-19 antibody therapy is welcome news for the partners, but rising vaccination rates plus three other competitors in Europe will limit revenues.

Paris, 19 May 2021
Paris, 19 May 2021: cafes and restaurants have reopened in France and other EU nations as vaccinations help to cut cases and reduce transmission. • Source: Getty Images

Vir Biotechnology and GlaxoSmithKline's COVID-19 antibody therapy sotrovimab has been given the green light for use in the European Union.

The EU regulator’s committee for human medicinal products (CHMP) has once again used a previously little-known mechanism, Article 5(3) of Regulation 726/2004, to provide an

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip